Clinical trials of WR-2721 with radiation therapy

Blumberg, Albert L.; Nelson, Diana F.; Gramkowski, Mary; Glover, Donna J.; Glick, John H.; Yuhas, John M.; Kligerman, Morton M.

doi:10.1016/0360-3016(82)90684-8

Cited by 56 publications

(20 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, these have focused on, either the enhancement of tumour cell radiosensitivity by overcoming the problem of hypoxia, using sensitisers, or the selective protection of normal tissues using radioprotectors. Such approaches have achieved limited success (Overgaard et al, 1992; Dische, 1992) and have often been hampered by problems of agent-associated toxicity (Blumberg et al, 1982;Overgaard et al, 1989).…”

mentioning

confidence: 99%

The modulation of radiation-induced damage to pig skin by essential fatty acids

Hopewell

Robbins²,

Aardweg³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

The ability of essential fatty acids (EFAs) to modulate radiation-induced normal tissue injury was assessed in pig skin. Female Large White pigs (approximately 25 Kg) received 3 ml/day orally of either an 'active' oil [So-1100, containing 9% gamma-linolenic acid (GLA)] or a 'placebo' oil (So-1129) for just 4 weeks before or for 4 weeks before and for 16 weeks after irradiation; localised irradiation of skin was with single doses of beta-rays from 22.5 mm diameter 90Sr/90Y plaques. The severity of the acute reaction, assessed in terms of erythema or moist desquamation, was significantly less in those pigs that received So-1100 both before and after irradiation, as compared with those receiving that oil only prior to irradiation and the 'placebo' groups. Dose modification factors (DMFs) of between 1.13-1.24 were obtained. A similar reduction in the severity of acute skin injury was seen in pigs receiving So-1100 for only 10 weeks after irradiation. Late skin damage, assessed in terms of late erythema or dermal necrosis, was also reduced with So-1100, with DMFs of 1.14-1.51. No such modification was observed if So-1100 was only administered for 4 weeks prior to irradiation. No adverse side-effects were apparent as a result of EFA administration. So-1100 may represent a safe and valuable method of increasing the therapeutic gain in radiotherapy.

show abstract

mentioning

confidence: 99%

The modulation of radiation-induced damage to pig skin by essential fatty acids

Hopewell

Robbins²,

Aardweg³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Synthesis of phosphoro derivatives of the aminothiols -cystaphos and especially WR-2721 -is an important step in this direction. But their use is also accompanied by side effects in animals of all species, in monkeys as well as in man (9,19,46). This demands action for decrease of the toxicity of these phosphoro derivatives of the aminothiols.…”

Section: Study Of the Antitoxic Effect Of Unithiol On Cystamine In Dogsmentioning

confidence: 99%

Study of the Antitoxic Effect of Unithiol on Cystamine in Dogs

Grachev¹,

Sverdlov²

2008

View full text Add to dashboard Cite

“…Early phase I trials with amifostine were not able to demonstrate a maximum-tolerated dose but did establish a tolerable dose range of 740-910 mg/m2 for use in phase II studies (Blumberg et al, 1982). Amifostine is generally well tolerated, although transient adverse events may be dose related and include hypotension, nausea, vomiting, sneezing, somnolence, a metallic taste during infusion, and occasional allergic reactions that may include rash, fever, and anaphylactic shock (Blumberg et al, 1982).…”

Section: Introductionmentioning

confidence: 99%

“…Amifostine is generally well tolerated, although transient adverse events may be dose related and include hypotension, nausea, vomiting, sneezing, somnolence, a metallic taste during infusion, and occasional allergic reactions that may include rash, fever, and anaphylactic shock (Blumberg et al, 1982). Although hypotension is the most clinically significant adverse event, treatment interruptions caused by a significant decline in blood pressure are rare, occurring in <5% of patients receiving amifostine.…”

Section: Introductionmentioning

confidence: 99%